Connor, Clark & Lunn Investment Management (CC&L)’s Myriad Genetics MYGN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.04M	Buy	1,407,860 +89,197	+7%	+$405K	0.02%	593
2026 Q1	$5.93M	Buy	1,318,663 +161,971	+14%	+$844K	0.01%	634
2025 Q4	$7.11M	Sell	1,156,692 -120,046	-9%	-$870K	0.02%	549
2025 Q3	$9.23M	Sell	1,276,738 -111,094	-8%	-$660K	0.03%	431
2025 Q2	$7.37M	Buy	1,387,832 +465,921	+51%	+$2.75M	0.03%	479
2025 Q1	$8.18M	Buy	921,911 +372,455	+68%	+$4.47M	0.04%	370
2024 Q4	$7.53M	Buy	549,456 +434,420	+378%	+$8.02M	0.03%	384
2024 Q3	$3.15M	Buy	115,036 +93,171	+426%	+$2.52M	0.02%	554
2024 Q2	$535K	Buy	+21,865	New	+$480K	﹤0.01%	1035
2024 Q1	–	Sell	-61,357	Closed	-$1.17M	–	1656
2023 Q4	$1.17M	Sell	61,357 -74,917	-55%	-$1.3M	0.01%	817
2023 Q3	$2.19M	Buy	136,274 +16,589	+14%	+$316K	0.01%	597
2023 Q2	$2.77M	Buy	119,685 +59,242	+98%	+$1.29M	0.01%	523
2023 Q1	$1.4M	Buy	60,443 +49,408	+448%	+$1M	0.01%	636
2022 Q4	$160K	Buy	+11,035	New	+$206K	﹤0.01%	1079
2021 Q1	–	Sell	-44,442	Closed	-$879K	–	1053
2020 Q4	$879K	Sell	44,442 -40,022	-47%	-$646K	0.01%	655
2020 Q3	$1.1M	Buy	+84,464	New	+$1.07M	0.01%	603
2019 Q1	–	Sell	-27,466	Closed	-$798K	–	1003
2018 Q4	$798K	Sell	27,466 -36,225	-57%	-$1.3M	0.01%	596
2018 Q3	$2.93M	Buy	63,691 +19,766	+45%	+$879K	0.02%	381
2018 Q2	$1.64M	Buy	43,925 +28,575	+186%	+$965K	0.01%	521
2018 Q1	$454K	Buy	+15,350	New	+$519K	﹤0.01%	584
2014 Q2	–	Sell	-40,100	Closed	-$1.51M	–	602
2014 Q1	$1.51M	Sell	40,100 -66,100	-62%	-$2.05M	0.01%	312
2013 Q4	$2.37M	Buy	106,200 +43,300	+69%	+$1.1M	0.02%	240
2013 Q3	$1.52M	Buy	62,900 +34,500	+121%	+$980K	0.01%	224
2013 Q2	$805K	Buy	+28,400	New	+$823K	0.01%	290

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MYGN Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Myriad Genetics (MYGN) stake by 6.8% in Q2 2026, buying an estimated $405K and bringing the position to 1,407,860 shares worth $8.04M. The position accounts for 0.02% of the portfolio, ranked #593.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MYGN in Q2 2013 and has held it in 24 quarters since. The position peaked at $9.23M in Q3 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 1,407,860 shares of Myriad Genetics worth $8.04M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 89,197 Myriad Genetics shares in Q2 2026, an estimated $405K.
Myriad Genetics made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #593 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Myriad Genetics in Q2 2013 and has held it in 24 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Myriad Genetics position peaked at $9.23M in Q3 2025.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.